Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda, MA Michaels… - Lupus science & …, 2021 - lupus.bmj.com
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda… - Lupus science & …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
[HTML][HTML] Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda… - Lupus Science & …, 2021 - ncbi.nlm.nih.gov
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda, MA Michaels… - Lupus Science & …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> In phase II and III trials,
anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1 …
anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1 …
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
R Tummala, G Abreu, L Pineda… - Lupus Science & …, 2021 - europepmc.org
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
Safety profile of anifrolumab in patients with active SLE: An integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda… - Lupus Science and …, 2021 - research.monash.edu
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …